NEW YORK (GenomeWeb) – AstraZeneca will use Bina Technologies' genome analysis software as an enterprise platform to support its development work across three therapeutic areas, the companies said today.

Under the collaboration agreement, the pharma company will adopt the Bina Genomic Management Solution (GMS) globally to support genomic data analysis and management as part of its development of drugs in oncology, cardiovascular and metabolic disease, respiratory disease, inflammation, and autoimmunity. AstraZeneca will also become the first member of the Bina Alliance Program.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The United Nations is to consider a ban on field testing gene drives at a meeting being held next week, Technology Review reports.

The Associated Press reports that gene-edited food may soon be for sale.

The US Department of Health and Human Services is beginning a series of meetings on human fetal tissue research, Stat News reports.

In Cell this week: epigenetic change linked to glioblastomas, rare and low-frequency variants contributing to multiple sclerosis risk, and more.